 |
| BICX Hits New High for the Year Up 76% |
|
 Hot Stock to Watch |
Company: BioCorRx Inc. (OTCQB: BICX)
|
Last:
Price: 0.1776
Change (%): + 0.0476 (36.62)
Volume: 338,296 |
 |
BioCorRx Inc. Announces Expansion of the Start Fresh Program to Include Treatment of Opioid Dependence
Los Angeles, March 4, 2014 (GLOBE NEWSWIRE) - BioCorRx Inc. (“the Company”) (OTCQB: BICX) is pleased to announce the expansion of their revolutionary Start Fresh Program. In light of an escalating problem to society, as well as patient demand the Company is opening up the program to treat opioid addiction. The abuse of prescription painkillers burdens the U.S. healthcare system with an estimated annual cost of 72 billion dollars, and according to the Centers for Disease Control prescription drug overdose deaths have more than quadrupled since 1999. While actual statistics on drug abuse are difficult to compile, CDC estimates that for every one death there are 825 non-medical users of prescription painkillers. “Expanding our cutting-edge treatment program to help individuals addicted to painkillers is a natural next step for us and we feel confident about grasping a piece of the estimated 1 billion dollars in annual revenue generated by this market” said Kent Emry, CEO of BioCorRx.
This past weekend a new and extremely controversial opioid analgesic, Zohydro ER manufactured by Zogenix, hit the market after receiving FDA approval in October. While the opioid treatment market is already sizeable, many experts are predicting it will grow substantially following the release of Zohydro. According to Physicians for Responsible Opioid Prescribing, Zohydro comes in capsules that can easily be crushed diminishing its time-release effect, thereby increasing the drug’s potential for abuse. Zohydro’s opioid-analgesic predecessors, Vicodin and Oxycontin, are both highly addictive and have contributed largely to the growing phenomena of prescription drug abuse in the United States. As long as the FDA sees fit to approve of stronger drugs such as Zohydro, those drugs have the potential to fall into the wrong hands. “Many more individuals may find themselves battling addiction to these types of drugs and could be in need of our type of innovative care,” stated Dr. George Fallieras, a medical consultant serving on the BioCorRx Advisory Board. Dr. Fallieras plans to use the Start Fresh Program with select opioid dependent patients in his independently owned clinics once they are medically cleared.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
